Cite
HARVARD Citation
Harbeck, N. et al. (n.d.). Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet oncology. 17 (3), pp. 357-366. [Online].